MiMedx Group Inc., a fast-growing tissue-graft developer, has financial ties to more than 20 doctors, according to a review of doctors’ disclosures by The Wall Street Journal, but the company hasn’t reported these payments to the government under a 2013 law. The company says its products, made from donated placental tissue, aren’t among those that require a disclosure of doctor payments. At least one of MiMedx’s direct competitors, Osiris Therapeutics Inc., regularly provides information on its ties to doctors and reported...

Source: Wall Street Journal February 22, 2018 12:00 UTC